Rapamycin holds significant therapeutic potential for various diseases; however, its clinical application is limited by several formulation challenges, primarily its extremely low aqueous solubility (2.6 μg/mL). To address this, nanoparticle-based delivery systems have emerged as a promising strategy to enhance solubility and enable sustained drug release. Currently, Fyarro® (Aadi Bioscience, Inc.), an albumin-bound nanoparticle formulation, is the only FDA-approved injectable rapamycin product. In this study, we aimed to develop and evaluate novel poly(ethylene oxide)-block-poly(ε-caprolactone)-α-tocopheryl succinate (PEO-b-PCL-α-TS) micelles and assess their potential as a delivery system for rapamycin. PEO-b-PCL copolymers with varying PCL/PEO ratios were prepared via ring-opening polymerization and modified by α-TS conjugation, as confirmed by (1)H NMR, GPC, XRD, DSC analyses. The optimum rapamycin-loaded micelles (PEO(2000)-b-PCL(4000)-α-TS) exhibited nano-sized particles (< 22 nm) with a narrow polydispersity index (<0.29), high drug encapsulation efficiency (â¥92 %), and enhanced solubility (>1.3 mg/mL). Stability studies demonstrated that encapsulation protected rapamycin from degradation, maintaining over 90 % drug retention for three months at 4 °C, while in vitro release studies showed sustained release, with 50 % of rapamycin released from PEO(2000)-b-PCL(4000)-α-TS micelles over 72 h. In vitro cytotoxicity assays revealed anticancer activity against lung carcinoma epithelial cells (A549), and the human colon adenocarcinoma cell line (HCT116). Minimal toxicity (â¥70 % viability) was observed in normal human fibroblast cells (HFF1). These results point to the potential of PEO-b-PCL-α-TS micelles as a promising nanocarrier system, offering improved rapamycin solubility, enhanced stability, sustained release, and effective anticancer activity.
Development, characterization, and in vitro evaluation of poly(ethylene oxide)-block-poly(ε-caprolactone)-α-tocopheryl succinate micelles as a novel nanocarrier for rapamycin delivery.
阅读:4
作者:Binkhathlan Ziyad, Alshememry Abdullah K, Balkhair Ahmad M, Ali Raisuddin, Alhudaithi Sulaiman S, Alobid Saad, Qamar Wajhul, Aodah Alhassan H, Vakili Mohammad Reza, Lavasanifar Afsaneh
| 期刊: | International Journal of Pharmaceutics-X | 影响因子: | 5.200 |
| 时间: | 2025 | 起止号: | 2025 May 29; 9:100341 |
| doi: | 10.1016/j.ijpx.2025.100341 | ||
特别声明
1、本文转载旨在传播信息,不代表本网站观点,亦不对其内容的真实性承担责任。
2、其他媒体、网站或个人若从本网站转载使用,必须保留本网站注明的“来源”,并自行承担包括版权在内的相关法律责任。
3、如作者不希望本文被转载,或需洽谈转载稿费等事宜,请及时与本网站联系。
4、此外,如需投稿,也可通过邮箱info@biocloudy.com与我们取得联系。
